November 2018

Boston, MA

REGISTER INTEREST

Day One
Wednesday 13th December, 2017

Day Two
Thursday 14th December, 2017

08.30
Morning Coffee and Registration

09.20
Chair’s Opening Remarks

FOOD AND MOOD – MODULATION OF THE GUT-BRAIN AXIS BY PROBIOTICS, PREBIOTICS AND DIET

Synopsis

Introduction and Purpose:
One way organizations are looking to modulate the relationship between intestinal microbes and brain function is through probiotic, prebiotic and dietary insight. The purpose of this theme will be to help elucidate common mechanisms and challenges associated with nutritional interventions that impact brain function and behavior.

 

09.30
Effects of Intermittent Fasting-induced Gut Microbiome Modulation on Autoimmunity in Multiple Sclerosis

Synopsis

  • Gut microbiome altered by fasting confers protection to MS mice models
  • Altered gut microbiome are probiotic related
  • Similar microbiome changes are identified in a pilot clinical trial

10.00
Involvement of the Microbiome Proteins in the Central and Local Regulation of the Appetite

Synopsis

• The presence of anti-Ghrelin and anti-alpha-MSH Ig in eating disorder patient
• The concept of molecular mimicry applied to neuropeptides
• Enterobacteriacae ClpB as a mimetic of alpha-MSH
• Central and local effect of the ClpB
• New model of the appetite regulation involving the microbiome

11.30
Morning Refreshments and Networking

12.00
Driving the Tidal Wave of Microbiome Discovery – a next Generation Platform for Exploring the Microbiome

  • Peter Christey Chief Executive Officer, General Automation Lab Technologies (GALT)

Synopsis

• A Traditional microbiology tools lack scale required for microbiome level insights
• New research tools are critical to understanding the complexity of the microbiome
• GALT’s novel array-based platform enables a highly parallelized approach to cultivation and screening of microbes

BUILDING A BUSINESS IN THE GUT-BRAIN AXIS – COMMERCIALIZING SCIENCE INTO SUCCESS

Synopsis

Introduction and Purpose:
Despite significant efforts from the scientific community to understand the gut-brain axis and its application to health and disease, is there a viable business model to commercially succeed from this emerging science? The purpose of this theme will be to look at the areas that need addressing when commercializing a nascent field of research.

10.30
Designed Microbiome Therapies Targeting the Microbes and Beyond

Synopsis

  • Learning how the gut microbiome plays an essential role in disease regulation and efficacy of therapies
  • Distinguishing a clear understanding as to whether dysbiosis is a cause or consequence of the diseases and assessing the equilibrium between the gut barrier and the immune system
  • Discussing the importance of multiple-target drug cocktails comprising of commensal bacteria with a particular focus on successful products that treat Irritable Bowel Syndrome (IBS)

12.20
Brain-Machine Interfaces to Measure Neural Signals- Gut Motility Data and Parkinson Disease

  • Todd Coleman Associate Professor, Bioengineering, UC San Diego

15.00
From Microbiome Explorations to Effective Innovative Therapies in Parkinson Disease

Synopsis

  • From biochemical mechanisms to proof of concept: how to design a new strategy for Parkinson Disease
  • Access patient microbiome information’s: a way for personalized treatment
  • Preclinical and clinical trials: the same road as pharmaceutical development?

15.30
Chair’s Closing Remarks

15.40
End of Inaugural Gut-Brain Axis Summit

13.20
Lunch and Networking

MICROBIOME DATA ANALYSIS – SOLVING THE GUT-BRAIN MYSTERY

Synopsis

Introduction and Purpose:
Research into the human microbiome and gut-brain axis has resulted in unprecedented amounts of complex data that can be difficult to identify results. The purpose of this theme is to review how novel computational methods and screening tools are being utilized to analyze complex microbial data. The purpose of this theme is to review how recent gut-brain research is being integrated in the development of novel diagnostic/screening tools.

14.30
Targeting the Gut Microbiome to Treat Neurological Conditions: Elucidating a Causal Relationship between the Gut and Disease

Synopsis

  • Harnessing the link between the gut microbiome and CNS using a suite of in vitro and in vivo approaches to develop a new class of therapeutics in ASD and Parkinson’s
  • A discussion of AB-1224, a first-in class commensal bacteria-based intervention for the treatment ASD and a summary of promising preclinical data
  • Reviewing the current hallmarks of success and looking to the future

12.50
Tools and Methods for Discovery in Microbial Community Studies with Billions of Sequences

Synopsis

  • Tools and techniques to analyze microbial communities
  • Community efforts to assess technical processing and maximize treatment effect sizes to facilitate microbiome studies
  • Meta-analyses: combining multiple studies to improve our understanding of the microbiome role in health and disease

11.00
Towards Psychobiotics – Microbiome, Brain and Behaviour

  • Caitlin Cowan Post-Doctoral Researcher, APC Microbiome Institute

Synopsis

  • A forward-thinking look at microbiota contributions to fundamental brain processes and behaviors
  • Probiotic and prebiotic effects on emotional, cognitive, systemic, and neural variables relevant to health and disease
  • Mechanistic insights to future psychobiotic development